Donislecel
Cellular therapy medication / From Wikipedia, the free encyclopedia
Donislecel, sold under the brand name Lantidra, is a cellular therapy medication used for the treatment of type 1 diabetes.[3][5] Donislecel is an allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells.[5] Donislecel is administered as a single infusion into the hepatic (liver) portal vein.[5]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Lantidra |
Other names | donislecel-jujn |
License data |
|
Routes of administration | Islet cell transplantation via intravenous infusion[1][2] |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Close
The most common adverse reactions include nausea, fatigue, anemia, diarrhea, and abdominal pain.[5]
Donislecel was approved for medical use in the United States in June 2023.[3][5]